Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 536

1.

Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis.

Puelles VG, Fleck D, Ortz L, Papadouri S, Strieder T, Böhner AMC, van der Wolde JW, Vogt M, Saritas T, Kuppe C, Fuss A, Menzel S, Klinkhammer BM, Müller-Newen G, Heymann F, Decker L, Braun F, Kretz O, Huber TB, Susaki EA, Ueda HR, Boor P, Floege J, Kramann R, Kurts C, Bertram JF, Spehr M, Nikolic-Paterson DJ, Moeller MJ.

Kidney Int. 2019 Mar 15. pii: S0085-2538(19)30318-7. doi: 10.1016/j.kint.2019.02.034. [Epub ahead of print]

PMID:
31155155
2.

Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Carter SA, Lightstone L, Cattran D, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette R, Malvar A, Radhakrishnan J, Rovin BH, Zhang H, Gutman T, Howell M, Logeman C, Shen JI, Teixeira-Pinto A, Alexander SI, Cho Y, Craig JC, Harris D, Johnson DW, Kerr PG, Ryan J, Viecelli AK, Wang AY, Wilkie M, Scholes-Robertson N, Tong A; SONG-GD Initiative.

Kidney Int. 2019 Jun;95(6):1280-1283. doi: 10.1016/j.kint.2019.01.047. No abstract available.

PMID:
31122702
3.

Novel parietal epithelial cell subpopulations contribute to focal segmental glomerulosclerosis and glomerular tip lesions.

Kuppe C, Leuchtle K, Wagner A, Kabgani N, Saritas T, Puelles VG, Smeets B, Hakroush S, van der Vlag J, Boor P, Schiffer M, Gröne HJ, Fogo A, Floege J, Moeller MJ.

Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30186-3. doi: 10.1016/j.kint.2019.01.037. [Epub ahead of print]

PMID:
31029503
4.

Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.

Lamina C, Kronenberg F, Stenvinkel P, Froissart M, Forer L, Schönherr S, Wheeler DC, Eckardt KU, Floege J.

Nephrol Dial Transplant. 2019 Apr 21. pii: gfz060. doi: 10.1093/ndt/gfz060. [Epub ahead of print]

PMID:
31006013
5.

Antimalarials in IgA Nephropathy: Did Our Supportive Therapy Armamentarium Just Increase?

Floege J.

Am J Kidney Dis. 2019 Apr 17. pii: S0272-6386(19)30639-0. doi: 10.1053/j.ajkd.2019.02.022. [Epub ahead of print] No abstract available.

PMID:
31005372
6.

Big science and big data in nephrology.

Saez-Rodriguez J, Rinschen MM, Floege J, Kramann R.

Kidney Int. 2019 Jun;95(6):1326-1337. doi: 10.1016/j.kint.2018.11.048. Epub 2019 Mar 5. Review.

PMID:
30982672
7.

Elastin imaging enables noninvasive staging and treatment monitoring of kidney fibrosis.

Sun Q, Baues M, Klinkhammer BM, Ehling J, Djudjaj S, Drude NI, Daniel C, Amann K, Kramann R, Kim H, Saez-Rodriguez J, Weiskirchen R, Onthank DC, Botnar RM, Kiessling F, Floege J, Lammers T, Boor P.

Sci Transl Med. 2019 Apr 3;11(486). pii: eaat4865. doi: 10.1126/scitranslmed.aat4865.

PMID:
30944168
8.

[Immunoglobulin A nephropathy].

Seikrit C, Rauen T, Floege J.

Internist (Berl). 2019 May;60(5):432-439. doi: 10.1007/s00108-019-0588-5. Review. German.

PMID:
30895344
9.

Disruption of CUL3-mediated ubiquitination causes proximal tubule injury and kidney fibrosis.

Saritas T, Cuevas CA, Ferdaus MZ, Kuppe C, Kramann R, Moeller MJ, Floege J, Singer JD, McCormick JA.

Sci Rep. 2019 Mar 14;9(1):4596. doi: 10.1038/s41598-019-40795-0.

10.

Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension.

van Roeyen CRC, Martin IV, Drescher A, Schuett KA, Hermert D, Raffetseder U, Otten S, Buhl EM, Braun GS, Kuppe C, Liehn E, Boor P, Weiskirchen R, Eriksson U, Gross O, Eitner F, Floege J, Ostendorf T.

Kidney Int. 2019 May;95(5):1103-1119. doi: 10.1016/j.kint.2018.11.031. Epub 2019 Feb 28.

PMID:
30827511
11.

Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study.

Schneider MP, Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Friedrich N, Janka R, Uder M, Schmieder RE, Eckardt KU.

Kidney Int Rep. 2018 Oct 11;4(2):267-274. doi: 10.1016/j.ekir.2018.10.004. eCollection 2019 Feb.

12.

Magnesium but not nicotinamide prevents vascular calcification in experimental uraemia.

Kaesler N, Goettsch C, Weis D, Schurgers L, Hellmann B, Floege J, Kramann R.

Nephrol Dial Transplant. 2019 Feb 1. doi: 10.1093/ndt/gfy410. [Epub ahead of print]

PMID:
30715488
13.

[Perspectives 2025 - Positions of the German Society of Internal Medicine].

Vogelmeier C, Floege J, Gamstätter T.

Dtsch Med Wochenschr. 2019 Feb;144(3):207-212. doi: 10.1055/a-0799-5146. Epub 2019 Jan 31. German.

PMID:
30703843
14.

Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Rovin BH, Caster DJ, Cattran DC, Gibson KL, Hogan JJ, Moeller MJ, Roccatello D, Cheung M, Wheeler DC, Winkelmayer WC, Floege J; Conference Participants.

Kidney Int. 2019 Feb;95(2):281-295. doi: 10.1016/j.kint.2018.11.008.

15.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
16.

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.

Thompson A, Carroll K, A Inker L, Floege J, Perkovic V, Boyer-Suavet S, W Major R, I Schimpf J, Barratt J, Cattran DC, S Gillespie B, Kausz A, W Mercer A, Reich HN, H Rovin B, West M, Nachman PH.

Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.

PMID:
30635299
17.

Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores).

Schimpf JI, Klein T, Fitzner C, Eitner F, Porubsky S, Hilgers RD, Floege J, Groene HJ, Rauen T.

BMC Nephrol. 2018 Nov 19;19(1):328. doi: 10.1186/s12882-018-1128-6.

18.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
19.

Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease.

Scheppach JB, Raff U, Toncar S, Ritter C, Klink T, Störk S, Wanner C, Schlieper G, Saritas T, Reinartz SD, Floege J, Janka R, Uder M, Schmieder RE, Eckardt KU, Schneider MP.

Hypertension. 2018 Oct;72(4):929-936. doi: 10.1161/HYPERTENSIONAHA.118.11608.

PMID:
30354716
20.

Urinary Biomarkers in the Prediction of Prognosis and Treatment Response in IgA Nephropathy.

Neuhaus J, Bauer F, Fitzner C, Hilgers RD, Seibert F, Babel N, Doevelaar A, Eitner F, Floege J, Rauen T, Westhoff TH.

Kidney Blood Press Res. 2018;43(5):1563-1572. doi: 10.1159/000494442. Epub 2018 Oct 22.

21.

Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss.

Zewinger S, Rauen T, Rudnicki M, Federico G, Wagner M, Triem S, Schunk SJ, Petrakis I, Schmit D, Wagenpfeil S, Heine GH, Mayer G, Floege J, Fliser D, Gröne HJ, Speer T.

J Am Soc Nephrol. 2018 Nov;29(11):2722-2733. doi: 10.1681/ASN.2018040405. Epub 2018 Oct 2.

PMID:
30279273
22.

[What is certain in the treatment of glomerulonephritis?]

Floege J, Boor P, Moeller MJ.

Internist (Berl). 2018 Dec;59(12):1268-1278. doi: 10.1007/s00108-018-0500-8. Review. German.

PMID:
30250965
23.

Magnesium Concentration in Dialysate: Is Higher Better?

Floege J.

Clin J Am Soc Nephrol. 2018 Sep 7;13(9):1309-1310. doi: 10.2215/CJN.08380718. Epub 2018 Aug 21. No abstract available.

PMID:
30131426
24.

YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy.

Gibbert L, Hermert D, Wang J, M Breitkopf D, Alidousty C, Neusser M, Cohen CD, Gröne E, Macheleidt I, Rauen T, Braun GS, Floege J, Ostendorf T, Raffetseder U.

Clin Immunol. 2018 Sep;194:67-74. doi: 10.1016/j.clim.2018.07.002. Epub 2018 Jul 3.

PMID:
30018024
25.

Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.

Sprague SM, Floege J.

Expert Opin Pharmacother. 2018 Jul;19(10):1137-1148. doi: 10.1080/14656566.2018.1491548. Epub 2018 Jul 9. Review.

PMID:
29985725
26.

IgA nephropathy: new insights into the role of complement.

Floege J, Daha MR.

Kidney Int. 2018 Jul;94(1):16-18. doi: 10.1016/j.kint.2018.03.009.

PMID:
29933843
27.

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.

Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.

Nephrol Dial Transplant. 2018 May 29. doi: 10.1093/ndt/gfy127. [Epub ahead of print]

PMID:
29846719
28.

[Screening: Let's Seize the Opportunity for Early Detection of Diseases].

Floege J.

Dtsch Med Wochenschr. 2018 Jun;143(11):761. doi: 10.1055/a-0594-5181. Epub 2018 May 28. German. No abstract available.

PMID:
29807372
29.

Risk of hospitalization associated with body mass index and weight changes among prevalent haemodialysis patients.

Carrero JJ, Cabezas-Rodríguez I, Qureshi AR, Floege J, Ketteler M, London G, Locatelli F, Memmos D, Goldsmith D, Ferreira A, Nagy J, Teplan V, Martínez-Salgado C, Fernández-Martín JL, Zoccali C, Cannata-Andia JB; COSMOS group.

Nefrologia. 2018 Sep - Oct;38(5):520-527. doi: 10.1016/j.nefro.2018.02.009. Epub 2018 Jun 11. English, Spanish.

30.

Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study.

Fernández-Martín JL, Dusso A, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Górriz JL, Rutkowski B, Bos WJ, Tielemans C, Martin PY, Wüthrich RP, Pavlovic D, Benedik M, Rodríguez-Puyol D, Carrero JJ, Zoccali C, Cannata-Andía JB; COSMOS group .

Nephrol Dial Transplant. 2019 Apr 1;34(4):673-681. doi: 10.1093/ndt/gfy093.

PMID:
29741651
31.

Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University.

Marx N, Noels H, Jankowski J, Floege J, Fliser D, Böhm M.

Clin Res Cardiol. 2018 Aug;107(Suppl 2):120-126. doi: 10.1007/s00392-018-1260-0. Epub 2018 May 4. Review.

PMID:
29728829
32.

Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.

Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A.

Hemodial Int. 2018 Oct;22(4):480-491. doi: 10.1111/hdi.12663. Epub 2018 Apr 15.

PMID:
29656600
33.

Inverse correlation between vascular endothelial growth factor back-filtration and capillary filtration pressures.

Kuppe C, Rohlfs W, Grepl M, Schulte K, Veron D, Elger M, Sanden SK, Saritas T, Andrae J, Betsholtz C, Trautwein C, Hausmann R, Quaggin S, Bachmann S, Kriz W, Tufro A, Floege J, Moeller MJ.

Nephrol Dial Transplant. 2018 Sep 1;33(9):1514-1525. doi: 10.1093/ndt/gfy057.

PMID:
29635428
34.

The new SFB/TRR219 Research Centre.

Noels H, Boor P, Goettsch C, Hohl M, Jahnen-Dechent W, Jankowski V, Kindermann I, Kramann R, Lehrke M, Linz D, Maack C, Niemeyer B, Roma LP, Schuett K, Speer T, Wagenpfeil S, Werner C, Zewinger S, Böhm M, Marx N, Floege J, Fliser D, Jankowski J.

Eur Heart J. 2018 Mar 21;39(12):975-977. doi: 10.1093/eurheartj/ehy083. No abstract available.

PMID:
29579229
35.

CTLA-4 Polymorphisms in Patients with IgA Nephropathy Correlate with Proteinuria.

Jacob M, Ohl K, Goodarzi T, Harendza S, Eggermann T, Fitzner C, Hilgers RD, Bolte A, Floege J, Rauen T, Tenbrock K.

Kidney Blood Press Res. 2018;43(2):360-366. doi: 10.1159/000488069. Epub 2018 Mar 8.

36.

Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.

Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P.

Kidney Int. 2018 Jun;93(6):1475-1482. doi: 10.1016/j.kint.2017.12.014. Epub 2018 Mar 7.

PMID:
29525393
37.

IgA nephropathy: toward more specific diagnosis (and rescue of snails).

Floege J.

Kidney Int. 2018 Mar;93(3):542-544. doi: 10.1016/j.kint.2017.10.028.

PMID:
29475546
38.

Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study.

Dimkovic N, Schlieper G, Jankovic A, Djuric Z, Ketteler M, Damjanovic T, Djuric P, Marinkovic J, Radojcic Z, Markovic N, Floege J.

Int Urol Nephrol. 2018 May;50(5):939-946. doi: 10.1007/s11255-018-1821-1. Epub 2018 Feb 13.

PMID:
29441480
39.

[Internal Medicine - from Guidelines to "Choosing Wisely"].

Floege J.

Dtsch Med Wochenschr. 2017 Dec;142(24):1785. doi: 10.1055/s-0043-118227. Epub 2017 Dec 5. German. No abstract available.

PMID:
29207420
40.

Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation.

Stamellou E, Floege J.

Nephrol Dial Transplant. 2018 Oct 1;33(10):1683-1689. doi: 10.1093/ndt/gfx322.

PMID:
29206932
41.

Sclerostin deficiency modifies the development of CKD-MBD in mice.

Kaesler N, Verhulst A, De Maré A, Deck A, Behets GJ, Hyusein A, Evenepoel P, Floege J, Marx N, Babler A, Kramer I, Kneissel M, Kramann R, Weis D, D'Haese PC, Brandenburg VM.

Bone. 2018 Feb;107:115-123. doi: 10.1016/j.bone.2017.11.015. Epub 2017 Nov 21.

PMID:
29175269
42.

PDGF in organ fibrosis.

Klinkhammer BM, Floege J, Boor P.

Mol Aspects Med. 2018 Aug;62:44-62. doi: 10.1016/j.mam.2017.11.008. Epub 2017 Nov 22. Review.

PMID:
29155002
43.

Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.

Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J.

J Am Soc Nephrol. 2018 Jan;29(1):317-325. doi: 10.1681/ASN.2017060713. Epub 2017 Oct 17.

44.

The longer the better: follow-up in seemingly 'benign' immunoglobulin A nephropathy.

Kunter U, Floege J.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1777-1779. doi: 10.1093/ndt/gfx236. No abstract available.

PMID:
28992065
45.

Complement C5a receptors C5L2 and C5aR in renal fibrosis.

Martin IV, Bohner A, Boor P, Shagdarsuren E, Raffetseder U, Lammert F, Floege J, Ostendorf T, Weber SN.

Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F35-F46. doi: 10.1152/ajprenal.00060.2017. Epub 2017 Sep 13.

46.

Macrophage Migration Inhibitory Factor Limits Renal Inflammation and Fibrosis by Counteracting Tubular Cell Cycle Arrest.

Djudjaj S, Martin IV, Buhl EM, Nothofer NJ, Leng L, Piecychna M, Floege J, Bernhagen J, Bucala R, Boor P.

J Am Soc Nephrol. 2017 Dec;28(12):3590-3604. doi: 10.1681/ASN.2017020190. Epub 2017 Aug 11.

47.

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V; TESTING Study Group.

JAMA. 2017 Aug 1;318(5):432-442. doi: 10.1001/jama.2017.9362.

48.

Mucosal corticosteroid therapy of IgA nephropathy.

Floege J.

Kidney Int. 2017 Aug;92(2):278-280. doi: 10.1016/j.kint.2017.05.021.

PMID:
28709593
49.

YB-1 orchestrates onset and resolution of renal inflammation via IL10 gene regulation.

Wang J, Djudjaj S, Gibbert L, Lennartz V, Breitkopf DM, Rauen T, Hermert D, Martin IV, Boor P, Braun GS, Floege J, Ostendorf T, Raffetseder U.

J Cell Mol Med. 2017 Dec;21(12):3494-3505. doi: 10.1111/jcmm.13260. Epub 2017 Jun 30.

50.

Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma.

Gajjala PR, Jankowski V, Heinze G, Bilo G, Zanchetti A, Noels H, Liehn E, Perco P, Schulz A, Delles C, Kork F, Biessen E, Narkiewicz K, Kawecka-Jaszcz K, Floege J, Soranna D, Zidek W, Jankowski J.

Hypertension. 2017 Aug;70(2):412-419. doi: 10.1161/HYPERTENSIONAHA.116.08906. Epub 2017 Jun 26.

PMID:
28652472

Supplemental Content

Loading ...
Support Center